Viking Therapeutics Q3 Net Loss Widens to $183.2 Million
Viking Therapeutics on October 28, 2026, reported its financial results for the third quarter and nine months ended September 30, 2026, posting a net loss of $183.2 million, or $1.55 per share, for the quarter, compared with a net loss of $90.8 million, or $0.81 per share, in the same period of 2025. The San Diego-based clinical-stage biopharmaceutical company ended the quarter with $960 million in cash, cash equivalents and short-term investments following a September financing. Research and…